BioMarin To Reduce Operating Expenses To Achieve ROCTAVIAN Profitability By End Of 2025; Focuses Commercial Operations On US, Germany, And Italy; Will Continue Monitoring And Support For Treated Patients
Author: Benzinga Newsdesk | August 05, 2024 04:02pm